Secondary Iron Overload
Open Access
- 1 January 2001
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2001 (1) , 47-61
- https://doi.org/10.1182/asheducation-2001.1.47
Abstract
Transfusion therapy for inherited anemias and acquired refractory anemias both improves the quality of life and prolongs survival. A consequence of chronic transfusion therapy is secondary iron overload, which adversely affects the function of the heart, the liver and other organs. This session will review the use of iron chelating agents in the management of transfusion-induced secondary iron overload.Keywords
This publication has 130 references indexed in Scilit:
- Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamineEuropean Journal of Pediatrics, 1996
- Iron concentration and distribution in the newborn liverLiver International, 1994
- Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelationThe Lancet, 1990
- Deferoxamine-induced growth retardation in patients with thalassemia majorThe Journal of Pediatrics, 1988
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985
- Magnetic-Susceptibility Measurement of Human Iron StoresNew England Journal of Medicine, 1982
- Hereditary HemochromatosisNew England Journal of Medicine, 1979
- PREVENTION OF IRON LOADING IN TRANSFUSION-DEPENDENT THALASSÆMIAThe Lancet, 1978
- Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron OverloadNew England Journal of Medicine, 1977